Future prospects of therapeutic clinical trials in acute myeloid leukemia

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

(2016) Céline Berthon et al.   Lancet Haematology

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts

(2015) Tapan M. Kadia et al.   AMERICAN JOURNAL OF HEMATOLOGY

Acute myeloid leukemia-Major progress over four decades and glimpses into the future

(2015) Hagop Kantarjian   AMERICAN JOURNAL OF HEMATOLOGY

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

(2015) Courtney D. DiNardo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Emerging therapeutic drugs for AML

(2015) E. M. Stein et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia

(2015) E. Estey et al.   BLOOD

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Targeting of folate receptor   on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells

(2015) R. C. Lynn et al.   BLOOD

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia

(2015) B. J. Wouters et al.   BLOOD

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials

(2015) Joshua P. Sasine et al.   BLOOD REVIEWS

Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

Germline Mutations in Predisposition Genes in Pediatric Cancer

(2015) Jinghui Zhang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Why Is Progress in Acute Myeloid Leukemia So Slow?

(2015) Elihu Estey   SEMINARS IN HEMATOLOGY

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2015) Nestor Ramos et al.   Journal of Clinical Medicine

Acute myeloid leukemia: 2014 Update on risk-stratification and management

(2015) Elihu H. Estey   AMERICAN JOURNAL OF HEMATOLOGY

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

(2015) Harald Herrmann et al.   Oncotarget

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

(2014) Jorge E. Cortes et al.   CANCER

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

(2014) B T Gjertsen et al.   LEUKEMIA

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

(2014) Pragya Srivastava et al.   LEUKEMIA RESEARCH

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation

(2014) Chunyan Cai et al.   STATISTICS IN MEDICINE

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

(2013) O. Abdel-Wahab et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Cancer chemoprevention: a rapidly evolving field

(2013) W P Steward et al.   BRITISH JOURNAL OF CANCER

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

(2013) Roelof Willemze et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

(2013) J.-A. Losman et al.   SCIENCE

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

(2012) Jerzy Holowiecki et al.   JOURNAL OF CLINICAL ONCOLOGY

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

(2011) Kathrin M. Bernt et al.   CANCER CELL

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2011) Eric J. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trials: A Long-term Investment With Promising Returns

(2011) M. R. Sharma et al.   JNCI-Journal of the National Cancer Institute

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

(2010) R. B. Walter et al.   BLOOD

Overall Survival: A Gold Standard in Search of a Surrogate

(2010) Sen H. Zhuang et al.   CANCER JOURNAL

A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies

(2010) S. K. Cheng et al.   CLINICAL CANCER RESEARCH

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research

(2010) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials

(2010) Hui Tang et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?

(2008) John K. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Accounting for patient heterogeneity in phase II clinical trials

(2007) J. Kyle Wathen et al.   STATISTICS IN MEDICINE